Formulary
Sulindac: Indications, Dosing, Side Effects and Interactions
Sulindac clinical drug profile including indications, dosing, side effects, cautions and interactions.
MedNext Academy | 3 min read
Sulindac: Indications, Dosing, Side Effects and Interactions
Sulindac clinical drug profile including indications, dosing, side effects, cautions and interactions.
Indications and dose
**Pain and inflammation in rheumatic disease and other musculoskeletal disorders,Acute gout**
- **Adult** (By Mouth): 200 mg twice daily for maximum duration 7-10 days in peri-articular disorders, dose may be reduced according to response; acute gout should respond within 7 days; maximum 400 mg per day.
Cautions
Allergic disorders; cardiac impairment (NSAIDs may impair renal function); cerebrovascular disease; coagulation defects; connective-tissue disorders; dehydration (risk of renal impairment); elderly (risk of serious side-effects and fatalities); heart failure; history of gastro-intestinal disorders (e.g. ulcerative colitis, Crohn's disease); history of renal stones (ensure adequate hydration); ischaemic heart disease; may mask symptoms of infection; peripheral arterial disease; risk factors for cardiovascular events; uncontrolled hypertension
Contraindications
Active gastro-intestinal bleeding; active gastro-intestinal ulceration; history of gastro-intestinal bleeding related to previous NSAID therapy; history of gastro-intestinal perforation related to previous NSAID therapy; history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes); history of recurrent gastro-intestinal ulceration (two or more distinct episodes); severe heart failure
Side effects
Frequency not known Acute psychosis; agranulocytosis; alopecia; angioedema; appetite decreased; arrhythmia; asthenia; asthma; bone marrow disorders; cholecystitis; confusion; constipation; Crohn's disease aggravated; depression; diarrhoea; dizziness; drowsiness; dyspnoea; dysuria; eye disorder; fever; gastrointestinal discomfort; gastrointestinal disorders; gynaecomastia; haemolytic anaemia; haemorrhage; hallucination; headache; hearing loss; heart failure; hepatic disorders; hyperglycaemia; hyperhidrosis; hyperkalaemia; hypersensitivity; hypersensitivity vasculitis; hypertension; increased risk of arterial thromboembolism; increased risk of infection; insomnia; leucopenia; malaise; meningitis aseptic (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible); mucosal abnormalities; muscle weakness; nausea; nephritis tubulointerstitial; nephrotic syndrome; nerve disorders; nervousness; neutropenia; oedema; oral disorders; palpitations; pancreatitis; paraesthesia; photosensitivity reaction; psychiatric disorder; renal impairment; respiratory disorders; seizure; severe cutaneous adverse reactions (SCARs); skin reactions; syncope; taste altered; thrombocytopenia; tinnitus; urine abnormalities; urine discolouration; vertigo; vision disorders; vomiting Side-effects, further information For information about cardiovascular and gastrointestinal side-effects, and a possible exacerbation of symptoms in asthma, see Non-steroidal anti-inflammatory drugs
Interactions
**Other interactions (2):**
- Combinations with increased risk for nephrotoxicity Care should be taken when using ciclosporin together with other active substances that exhibit nephrotoxic synergy such as: aminoglycosides...
- Tabulated list of Colestyramine drug-drug interactions: Drug Class Drug(s) Anti-arrhythmics Amiodarone Anti-convulsants Valproate Anti-infectives Vancomycin, tetracycline Antimetabolites...
Pregnancy
Important safety information For sulindac MHRA/CHM advice: NSAIDs: potential risks following prolonged use after 20 weeks of pregnancy (June 2023) See Non-steroidal anti-inflammatory drugs .
Breast feeding
Use with caution during breast-feeding.
Hepatic impairment
Manufacturer advises caution in mild to moderate impairment; avoid in severe impairment.
Renal impairment
In general, for NSAIDs the MHRA advises to avoid where possible; if necessary, use with caution (risk of fluid retention and further renal impairment, including renal failure). For sulindac , avoid in severe impairment. M
Medicinal forms
Medicinal forms No licensed medicines listed.
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Sulindac in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

